Neomycin inhibits the angiogenic activity of fibroblast and epidermal growth factors.
Neomycin inhibits the angiogenic activity of fibroblast and epidermal growth factors.
复制标题
DOI：
10.1006/bbrc.2001.5668
复制
发表时间：
2001-10
影响因子：
3.1
通讯作者：
G. Hu
中科院分区：
文献类型：
--
作者：
G. Hu
新霉素已被证明可以阻断内皮细胞中血管生成素的核易位，从而抑制其诱导血管生成的能力。我们在这里报道了新霉素也是一种有效的血管生成抑制剂，它可以抑制酸性成纤维细胞生长因子、碱性成纤维细胞生长因子和表皮生长因子诱导的血管生成，所有这些都发生核易位，而血管内皮生长因子不发生核易位。因此，阻断核易位似乎是新霉素抗血管生成作用的一般机制，适用于那些需要核易位进行血管生成的血管生成因子。这些结果以及已知的毒性和药代动力学特征使新霉素及其类似物成为血管生成的良好候选抑制剂，可能被开发为抗肿瘤药物。
Neomycin has been shown to block nuclear translocation of angiogenin in endothelial cells, thereby inhibiting its capacity to induce angiogenesis. We report here that neomycin is also an effective inhibitor of angiogenesis induced by acidic fibroblast growth factor, basic fibroblast growth factor, and epidermal growth factor, all of which undergo nuclear translocation, but not that of vascular endothelial growth factor which does not undergo nuclear translocation. Blocking nuclear translocation, therefore, seems to be a general mechanism for the antiangiogenesis action of neomycin applicable to those angiogenic factors that require nuclear translocation for angiogenesis. These results along with the known toxicity and pharmacokinetics profiles make neomycin and its analogues good candidate inhibitors of angiogenesis that might be developed as antitumor agents.